The Covid-19 vaccine developed in the UK by the University of Oxford and AstraZeneca can protect 70.4% of people from the disease and - in an unexpected result - up to 90% if a lower first dose is used, the trial final.
The Oxford vaccine is the third to produce effective results, after Pfizer / BioNTech and Moderna , whose vaccines have been developed with a different technology. Both vaccines are reported to be almost 95% effective, while Pfizer has applied for a license in the US and UK.
Although the results of the Oxford vaccine may not look as good as those of Pfizer / BioNTech and Moderna, the scientists say they are not comparable because they have included in the study people with moderate symptoms as well as seriously ill people, otherwise by the other two. Their vaccine seems to have an advantage because it is refrigerated, easily transported and can be used anywhere in the world. It is also cheaper, about £ 3 (about ALL 400) compared to the price of other vaccines, just over £ 20 (about ALL 2,700).
The UK has ordered 100 million doses of the Oxford vaccine, which is essential to its pandemic vaccination plans. Production has already begun and 4 million doses have been supplied so far, which cannot be used until the vaccine is licensed.
The Oxford vaccine has been shown to work in both the elderly and the young. There are indications that it may also help stop the transmission of the disease.
- The Committee of Experts talks about the situation in the country: What will happen to schools and universities
- This is why health experts advise you not to gather in groups during the holidays
- Less common symptoms of Covid-19 should not be overlooked
- Why Covid-19 is killing more men than women, even in Albania
- When is the right time to take vitamins during the day
- Covid symptoms usually appear in this order
Source: Guardian
